For decades, the survival rate for glioblastoma (GBM) has remained nearly stagnant, and currently the 5-year survival rate is only 5%. There is an unmet medical need for therapeutic development, as GBM is the most common primary brain tumor, yet only four FDA approved drugs have been ...
Two-, 3-, 4-, and 5-year overall and progression-free survival (PFS) rates for patients who received TTFields with adjuvant temozolomide were significantly improved over patients who received temozolomide alone, reported Roger Stupp, MD, professor of neurological surgery at Northwestern University...
Glioblastoma Multiforme (GBM) is the most common type of primary intracranial tumour, with high mortality and recurrence rates and a low cure rate; it has a 5 year relative survival rate of only 5–8% [1]. Due to the specific location and high metastasis rate of glioma and the complexity...
GBMs have the highest incidence rate (3.2 per 100,000 population) and the highest number of cases of all malignant tumors with 12,760 cases projected for 2018 [1]. Unfortunately, the 5-year survival rate for glioblastomas is 5.5% [1], and there are no current effective therapies for ...
It was approved for patients with newly diagnosed and recurrent GBM [3,4,5,6,7]. The EF-14 clinical trial demonstrated that adding TTFields to maintenance temozolomide chemotherapy following radiotherapy (RT) significantly improved the progression-free survival (PFS) and overall survival (OS) rates...
[1]. The conventional treatment for GBM is surgical resection, followed byradiochemotherapyfor 6 weeks and adjuvanttemozolomidefor 6 months. However, the therapeutic effect is poor, as the five-yearsurvival rateof GBM patients is only 5% [1]. Recent studies aiming to improve treatment efficiency...
According to the World Health Organization, Glioblastoma multiforme (GBM) is the most common form of primary malignant brain cancer in adults with a 5-year survival rate of 4–5%1. Despite 75 years of research, the projected survival with treatment is only 15 months after diagnosis. Many promi...
“The 2-year annual survival rate is meaningful, and [Optune] resulted in a 30% absolute increase in survival. We are getting to something that is at least meaningful to patients and their families in terms of longer time to be together,” said Stupp. Further, survival benefit in terms of...
Despite advances in neurosurgical technology and techniques, the survival rate of GBM patients has remained relatively unchanged. The main treatments for GBM are associated with difficulties resulting from incomplete tumor resection and recurrence. In such situations, Photodynamic Therapy (PDT) is increasing...
The AUCs for 1, 3, and 5-year overall survival of glioma patients based on the CGGA data- base were 0.731, 0.822 and 0.841, respectively (Fig. 4C). The AUCs for 1, 3, and 5-year overall survival of gli- oma patients based on the TCGA database were 0.862, 0.889 and 0.851, ...